-
5 days ago | 
ajmc.com | Hayden E. Klein |Merrill Stewart
Captions were auto-generated. Cardiac positron emission tomography (PET) stress testing is emerging as a more accurate tool for assessing coronary artery disease (CAD), helping to reduce the need for invasive diagnostic procedures that may offer little to no clinical benefit, especially for patients with stable disease. In an interview with The American Journal of Managed Care® (AJMC®), Merrill H.
-
6 days ago | 
ajmc.com | Hayden E. Klein
Both low and high daily energy intake were associated with increased all-cause mortality among men with metabolic dysfunction–associated steatotic liver disease (MASLD), but not women, according to a study published in Scientific Reports.1 MASLD affects a third of adults in the US and is independently linked to higher rates of diabetes-related and all-cause mortality.2 Despite this, experts say there is a lack of robust evidence guiding long-term nutritional management in MASLD.1 To address...
-
6 days ago | 
ajmc.com | Hayden E. Klein |Mohit Narang
Captions were auto-generated. For patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for years, switching to zanubrutinib may offer significant advantages such as fewer cardiac events and a smoother clinical workflow, according to Mohit Narang, MD, managing partner at Maryland Oncology Hematology.
-
1 week ago | 
ajmc.com | Hayden E. Klein
There are currently 18.6 million cancer survivors living in the US, according to the American Cancer Society, and this number is expected to climb past 22 million in the next decade.1 With a total population over 341 million, this means about 5.5% of the country is living with a history of cancer.2 These findings were published in the American Cancer Society journal CA: A Cancer Journal for Clinicians, and are based on data from the Surveillance, Epidemiology, and End Results (SEER) cancer...
-
1 week ago | 
ajmc.com | Hayden E. Klein
The activin signaling inhibitor sotatercept (Winrevair; Merck) not only maintained a consistent safety profile over a median 2.5 years of follow-up in individuals with pulmonary arterial hypertension (PAH), but also significantly reduced mortality compared with placebo, according to analyses presented at the American Thoracic Society (ATS) 2025 International Conference.
-
1 week ago | 
ajmc.com | Hayden E. Klein
HHS Secretary Robert F. Kennedy, Jr, announced that the CDC will no longer recommend routine COVID-19 vaccines for pregnant women and healthy children.1In a video posted on social media, Kennedy said he “couldn’t be more pleased” to announce the guidance removal alongside Jay Bhattacharya, MD, PhD, director of the National Institutes of Health (NIH), and Marty Makary, MD, MPH, commissioner of the FDA.
-
1 week ago | 
ajmc.com | Hayden E. Klein
A home air filtration intervention showed a small, nonsignificant benefit for infants recovering from bronchiolitis, while cardiac imaging in school-aged children born preterm revealed signs of right ventricular hypertension in nearly a quarter of participants. Meanwhile, a quality improvement initiative successfully increased independent rounding among senior pediatric fellows and improved perceptions of confidence and communication.
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
An oral, pharmaceutical-grade cannabidiol (CBD) solution was well tolerated and showed no concerning effects on heart rhythm or overall safety in patients with a history of heart disease or major cardiovascular risk factors, according to findings presented at the European Society of Cardiology (ESC) Heart Failure Congress 2025.1 The randomized, double-blind trial evaluated a pharmaceutically manufactured, good manufacturing practice (GMP)–grade CBD drug in 89 adults with a history of...
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
Patients with chronic obstructive pulmonary disease (COPD) and elevated eosinophil counts may benefit from treatment with mepolizumab, according to new data presented at the American Thoracic Society (ATS) 2025 International Conference. Findings from the COPD-HELP and MATINEE trials suggest the IL-5 inhibitor could reduce exacerbation rates and improve aspects of quality of life, particularly in individuals with longer-standing disease or those at high risk for hospitalization.
-
2 weeks ago | 
ajmc.com | Hayden E. Klein
Nerandomilast significantly slowed lung function decline in patients with progressive pulmonary fibrosis (PPF), according to results from the phase 3 FIBRONEER-ILD trial.1In the 52-week, double-blind study, patients who received nerandomilast had a significantly smaller drop in forced vital capacity (FVC) compared with placebo, whether or not they were taking background nintedanib.
